VCEL: Vericel Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Vericel: 1-Year and 5-Year Forecast Outlook and Rating
Vericel (VCEL) has an immediate No Action - Keep Monitoring consensus AI recommendation, based on 11 AI analysts.
The 1-year target is $55.3 for , with -3.86% expected return (-3.86% including net dividends) and a SELL ALL rating.
The 5-year target is $77.8 for , with +35.26% expected return (+35.26% including net dividends) and a NEUTRAL rating.
Latest available market price: USD 57.5, as of 20 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 0% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Vericel Flagship Insight
A Funded Factory Shifts the Test From Growth to Shareholder Earnings
High consensus centers on cartilage-treatment adoption and post-construction manufacturing leverage, but shareholder gains depend on valuation discipline, insurance conversion and equity-compensation dilution. Burn care diversifies demand without guaranteeing federal procurement. Ankle expansion offers late-horizon optionality; elevated discount rates and competing single-stage procedures challenge the premium.
How were the Investment Thesis and Forecasts created?
11 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Machiavelli (Insider)
Warren Buffett (Value Purist)
Superintelligence (Anthropologist)
Ray Dalio (Strategist)
Elon Musk (Visionary)
Universal Investor (Polymath)
Sherlock Holmes (Whistleblower)
J.P. Morgan (Titan)
Michael Burry (Vulture)
Ran across these frontier AI models
Google Gemini 4 Hydrogen
OpenAI GPT-6.1 Sol
Anthropic Claude Opus 5.5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Vericel: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Vericel at the latest market close (20 Nov 2026): $13,526 by Nov 2031 versus $14,502 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
Vericel's investment case is a contest between operating leverage and shareholder capture. MACI Arthro broadens surgical access, while completed Burlington capacity allows implant growth to outpace manufacturing and commercial costs. Burn Care adds diversification, but optional federal procurement is not guaranteed recurring revenue. The stock already capitalizes substantial earnings maturation, making valuation sensitive to slower growth and recurring equity compensation. The strongest counterargument is that established surgeon utilization can compound knee-led cash earnings without ankle approval. Primary disclosures support that mechanism, but do not establish rapid buyback-driven share shrinkage, frictionless reimbursement or permanent premium multiples.
Key insights
- Lower construction spending improves financing flexibility, but compensation-funded cash flow can finance dilution offsets rather than increase each remaining shareholder's economic claim.
- Arthroscopy reduces implantation friction without eliminating biopsy logistics, so patient conversion and selling productivity matter more than the theoretical surgeon addressable market.
- Ankle approval would monetize existing infrastructure, creating asymmetric incremental economics; its uncertain clinical timetable argues against treating that additional growth duration as baseline.
Continue reading Vericel analysis with Base subscription
See Base accessVericel: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 57.5, as of 20 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 0% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 11 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 13 Nov 2026 at USD 57. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|---|---|---|---|
| $54.3 | -4.69% | -5.60% | -5.60% | Premium valuation faces pressure ahead of annual results as investors weigh elevated discount rates against expected year-end implant strength. Upcoming guidance and competing-procedure reimbursement developments matter more than extending the recent momentum narrative without fresh earnings evidence. | $52.5 | $58.1 | $736 | |
| $52.1 | -4.06% | -9.42% | -9.42% | Initial annual guidance and seasonally softer first-quarter procedures expose the cost of commercial expansion and recurring equity awards. Healthy underlying demand offers support, but the weighted scenario favors valuation digestion before operating leverage becomes more visible. | $48.8 | $55.1 | $724 | |
| $53.5 | +2.67% | -6.99% | -6.99% | A seasonal recovery in procedures and better utilization by trained surgeons begin translating the expanded commercial footprint into implant revenue. Competitive adoption remains disputed, but improving conversion and expense absorption support a recovery in confidence. | $45.9 | $57.3 | $722 | |
| $55.3 | +3.49% | -3.86% | -3.86% | Established surgeon utilization and higher manufacturing throughput strengthen the earnings argument beyond headline biopsy growth. Commercial burn adoption adds diversification, while possible UK progress remains incremental rather than necessary for the projected improvement in operating performance. | $44.0 | $60.2 | $724 | |
| $56.0 | +1.20% | -2.64% | -2.64% | Year-end implant scheduling supports cash generation from existing infrastructure, but development budgets and overseas preparation limit earnings upgrades. The balance favors modest progress rather than a broad rerating, with dilution offsets still absorbing some available cash. | $44.4 | $60.3 | $735 | |
| $55.9 | -0.14% | -2.82% | -2.82% | The spring reporting window pits recurring procedure seasonality and launch spending against maturing surgeon cohorts. These forces nearly balance, with reimbursement friction and competitive scrutiny narrowly outweighing the benefit of slower expense growth in stronger scenarios. | $42.3 | $61.3 | $752 | |
| $57.5 | +2.88% | -0.03% | -0.03% | Higher implant throughput spreads fixed facility costs across a broader revenue base, while established sales territories become more productive. Gradual overseas access can help, but domestic conversion and manufacturing utilization remain the principal sources of earnings support. | $42.3 | $63.2 | $754 | |
| $59.1 | +2.72% | +2.75% | +2.75% | Improving operating efficiency and a broader cartilage-and-burn earnings base support continued progress. Approaching statutory exclusivity expiration restrains enthusiasm, although the scenario does not equate that milestone with immediate competitor entry or loss of manufacturing differentiation. | $41.4 | $66.3 | $780 | |
| $61.0 | +3.16% | +6.05% | +6.05% | Peak implant-season cash generation becomes more important than exclusivity headlines if no immediate replacement product emerges. Manufacturing complexity and surgeon relationships support continuity, while routine payer scrutiny prevents interpreting the milestone as proof of permanent pricing power. | $43.0 | $68.3 | $802 | |
| $60.6 | -0.66% | +5.35% | +5.35% | First-quarter seasonality and competition for overlapping procedures temporarily temper confidence in growth duration. Better commercial productivity cushions the pressure, but the weighted scenario still requires evidence that stronger enterprise earnings reach shareholders after compensation and reinvestment. | $42.6 | $71.1 | $819 | |
| $62.7 | +3.52% | +9.01% | +9.01% | Repeat utilization by existing surgeons provides a growth lever beyond adding new accounts. Higher factory throughput and measured instrument adoption strengthen earnings expectations, while ankle-trial progress remains optional upside rather than a necessary source of current revenue. | $43.9 | $72.5 | $821 | |
| $65.1 | +3.78% | +13.18% | +13.18% | Operating and selling-cost absorption increasingly narrow the gap between attractive product margins and reported earnings. Continued knee growth supports confidence without requiring ankle sales; repurchases help only to the extent they exceed ongoing equity issuance. | $45.2 | $76.1 | $842 | |
| $67.2 | +3.22% | +16.83% | +16.83% | Year-end procedures and a larger commercial burn-care base reinforce the cash-generation thesis. Investors increasingly assess repeatable earnings rather than construction completion, with compensation, taxation and procurement timing still limiting how generously that progress is capitalized. | $47.0 | $78.4 | $863 | |
| $67.6 | +0.68% | +17.52% | +17.52% | Growing expense absorption increasingly cushions the usual spring procedure trough, allowing modest earnings-led progress. Development commitments and a gradually normalizing tax burden absorb part of the benefit, keeping improving operations from becoming an unrestricted cash-distribution story. | $47.5 | $80.7 | $871 | |
| $69.0 | +2.03% | +19.96% | +19.96% | Maturing knee penetration and evidence-generation costs temper gains, while established surgeon usage and higher capacity utilization keep earnings expanding. Ankle-readout anticipation supplies optionality, not assumed approval; disagreement centers on competitive intensity and the eventual commercialization timetable. | $48.9 | $82.4 | $874 | |
| $71.5 | +3.59% | +24.30% | +24.30% | Commercial discipline and broader utilization support continued improvement despite slower account additions. Clinical milestones may extend perceived growth duration, but the stronger evidence remains recurring implant economics and the conversion of gross profit into reported operating earnings. | $49.9 | $85.6 | $896 | |
| $73.2 | +2.45% | +27.26% | +27.26% | Year-end implant activity and accumulated liquidity support confidence in a more mature franchise. The scenario increasingly depends on repeatable conversion and sensible capital allocation, while any ankle filing or supply localization remains conditional rather than assured. | $51.4 | $87.4 | $912 | |
| $73.8 | +0.86% | +28.30% | +28.30% | More resilient underlying earnings offset much of the seasonal procedure slowdown, supporting limited progress. Continued equity grants and mature knee competition constrain shareholder capture, while established infrastructure reduces the need for another major construction spending cycle. | $50.8 | $90.0 | $924 | |
| $75.7 | +2.50% | +31.61% | +31.61% | Incremental utilization and modest international contribution sustain earnings growth as domestic adoption matures. Any early ankle commercialization would enhance the outcome, but the central support remains knee-led cash generation after ordinary reinvestment and continuing compensation costs. | $51.8 | $91.8 | $939 | |
| $77.8 | +2.84% | +35.26% | +35.26% | The business approaches a steadier earnings profile in which operating growth, rather than expanding valuation multiples, supports appreciation. Remaining disagreement concerns durable margins and diluted shareholder participation, with transformative clinical or acquisition outcomes outside the central case. | $52.3 | $94.6 | $965 |
Show remaining 18 quartersCollapse to first 2 quarters
All 20 quarters are displayed in the table above.
Vericel Stock Analysis & Scenarios Deep Dive
Vericel: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? November 2026 analyst-upgrade coverage and repeated company guidance increases indicate optimism that MACI can sustain strong growth and convert new capacity into premium margins. Rich supplied multiples imply substantial execution is already expected. However, analyst counts and reported rally measurements conflict, and no independently verified positioning survey is supplied; descriptions of universal enthusiasm exceed the evidence.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd modestly overestimates near-term value, but the evidence does not establish a large, durable mispricing. The underappreciated connection is that lower construction spending boosts cash flow while recurring equity awards can absorb the benefit through dilution or offsetting repurchases. That makes per-share cash earnings, not adjusted margins, the relevant valuation anchor. The strongest challenge is that record biopsies and established surgeon utilization may sustain profitable growth long enough for earnings to absorb the starting premium.
Repricing Catalyst
What could make the market recognize and close that gap? Initial 2027 guidance, expected with late-February annual results, is the first hard test of whether recent growth can translate into GAAP earnings. A growth outlook below 18% or weak conversion could deflate the near-term premium; sustained growth with slower expense increases would challenge that concern. Subsequent 2027 results provide confirmation, while funded UK access and MASCOT milestones around 2030 could extend growth duration rather than guarantee repricing.
Vericel: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Mixed
- Volatility Regime
- High Erratic
- Convergence Cycle Position
- Mixed
Volatility expectations converge, but cycle interpretations split between momentum, overshoot and growing awareness of operating maturation. The decisive tension is whether strong commercial evidence sustains the premium or merely delays normalization, making earnings confirmation more useful than sentiment-based timing.
Macro Regime Fit
Does the current market environment support the thesis? The setup is mixed, with a valuation headwind. Elevated discount rates penalize earnings expected far into the future, while substantial liquidity limits financing pressure. Medical need supports demand, but schedulable knee procedures remain exposed to patient costs and authorization delays. Geopolitical disruption matters specifically through NexoBrid supply, not the entire manufacturing franchise.
Advisor Disagreement
What do our AI Advisors disagree about most? The central dispute is how much valuation compression accompanies successful execution, not whether current sales are improving. Cautious paths assume rapid normalization toward mature medtech multiples; stronger paths retain a premium supported by surgeon utilization and margin expansion. A separate economic disagreement concerns whether single-stage alternatives materially affect near-term conversion. Some numerical differences instead reflect definitions: long-term versus total leases, trailing versus guided adjusted EBITDA, and unreconciled cash-flow bridges. Trial-registry timing also weakens early ankle-approval assumptions. Sustained MACI growth alongside rising GAAP margins and disciplined diluted share counts would resolve the most consequential debate.
Thesis Change
What changed in the thesis since the previous forecast? The operating-leverage thesis survives, but current evidence shifts the investment case from cash-flow underpricing toward caution about shareholder-level earnings capture. -- The earlier case treated post-construction cash flow and repurchases as sources of mild underpricing. Current disclosures make dilution offsets, lease commitments and the adjusted-to-GAAP gap more central, weakening that valuation advantage. -- The previous ankle opportunity assumed an early approval window. The supplied trial-registry estimate places primary completion around 2030, reducing near-term optionality; authorization and reimbursement also remain separate hurdles for international expansion.
Vericel: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (at least 75% probability of occurrence, as generation guidance). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Arthroscopy widens the adoption funnel | Innovation And Product | +35% | +65% | Less invasive implantation broadens practical surgeon participation without requiring a new cellular product. Record biopsies and sustained MACI growth support continued penetration as sales territories mature. Earnings benefit from additional implants and better selling productivity, although arthroscopy does not eliminate the biopsy stage or guarantee that every recruited surgeon generates recurring procedures. |
| Capacity shifts from construction to contribution | Operational Efficiency | +25% | +65% | Burlington changes the growth constraint from installed capacity to utilization. With major construction spending behind the company, additional implant volume can spread manufacturing and commercial overhead across more revenue. This supports earnings and cash generation over several years, but validation, parallel-site operations and depreciation make the benefit gradual rather than immediate. |
| Burn care broadens the earnings base | Sector And Industry | +17% | +30% | Epicel and commercial NexoBrid adoption diversify demand beyond scheduled knee reconstruction. Funded BARDA base activities add procurement visibility, while a broader burn-center footprint supports product utilization. The earnings contribution should persist, but severe-burn incidence remains uneven and the headline contract ceiling includes optional work that should not be treated as guaranteed sales. |
| Self-funding preserves strategic choices | Capital Allocation | +10% | +12% | Substantial cash and investments, no funded bank debt and improving internal cash generation allow development and commercial expansion without dependence on expensive external capital. Selective repurchases can offset equity awards and protect per-share participation. The durable benefit is financing flexibility, not an assumed mechanical reduction in diluted shares or automatic buyback accretion. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (at least 75% probability of occurrence, as generation guidance). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Growth must earn the premium | Macroeconomic And Macrofinancial | -35% | -0.0% | The starting valuation already anticipates substantial commercialization success. As growth matures, investors are likely to pay less for each dollar of earnings, particularly under elevated discount rates. This is primarily a price constraint rather than an operating-earnings decline; sustained execution or lower yields could soften, but not automatically remove, the adjustment. |
| Single-stage alternatives contest the workflow | Competitive Positioning | -14% | -22% | Competing scaffolds challenge the inconvenience of staged treatment, increasing selling and evidence-generation requirements for overlapping lesions. Coding progress can improve access without proving superiority to MACI. The reported 2028 data-exclusivity expiration shifts attention toward manufacturing know-how and remaining patents; it does not establish immediate biosimilar entry or eliminate clinical differentiation. |
| Clinical need still faces gatekeepers | Regulatory | -17% | -30% | Insurance authorization, deductibles and completion of two procedures limit how much clinical demand becomes implant revenue. These recurring constraints persist even with surgeon training and currently strong access. They restrain conversion and realized pricing while adding reimbursement-support costs; a coordinated adverse coverage decision would be a separate downside event, not this baseline friction. |
| Equity awards tax shareholder capture | Management And Governance | -10% | -20% | Recurring stock compensation is already expensed in GAAP earnings but added back in operating cash flow and adjusted profitability. Continuing grants therefore create an ownership cost that cash-flow headlines can obscure. Repurchases may largely offset issuance rather than increase each investor's claim, keeping per-share progress below enterprise-level earnings growth. |
Vericel: What Could Break or Accelerate the Thesis
Event Risk Score: High 77/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Coverage reset breaks implant conversion | 30% | -35% | A major payer's implemented coverage restriction, potentially reinforced by uptake of single-stage alternatives during 2027–2029, could break biopsy-to-implant conversion. Revenue would slow while cleanroom and selling costs remained fixed, hitting earnings and the premium multiple. Existing access, surgeon experience and absent head-to-head proof of competitor superiority keep this an adverse event, not the baseline. |
| Manufacturing hold interrupts personalized supply | 16% | -45% | A documented contamination incident or regulatory shipment restriction during 2027–2031 could interrupt patient-specific production while occupancy and remediation costs continue. Lost procedures and damaged surgeon confidence would amplify the earnings impact. Validated facilities and partial legacy-site resilience limit probability, but cannot provide instant replacement supply; an ordinary inspection observation alone would not establish this event. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Ankle approval unlocks another joint | 40% | +35% | A positive MASCOT readout followed by FDA ankle-label approval around 2030–2031 would extend existing manufacturing and sports-medicine infrastructure into another joint. The supplied registry timing makes earlier commercialization speculative. Clinical efficacy, follow-up, review and reimbursement must align, keeping probability below a majority; successful access would add high-contribution procedures and lengthen the franchise's growth duration. |
| Strategic acquisition crystallizes distribution synergies | 22% | +40% | A signed acquisition agreement with an orthopedic or regenerative-medicine buyer during 2027–2031 could bring forward the value of broader distribution and shared commercial infrastructure. Removing duplicated overhead could improve combined cash generation and support a control premium. Probability remains limited because no sale process is established, specialized manufacturing complicates integration, and the existing valuation constrains deal economics. |
Company Financial AnalysisVericel: Earnings and Financials Analysis by AI
Financial figures available as of Nov 16, 2026. Only filings and source records available by this analysis date are included. View latest Vericel financials here.
Earnings and financials
Vericel's SEC-filed Q3 FY2026 release and the supplied TTM figures through September 2026 show a real commercial improvement: trailing revenue reached $324 million, and quarterly sales grew 26%. MACI volume, pricing and Arthro adoption improved alongside stronger burn-care demand. Slower expense growth than sales supports genuine operating leverage rather than a purely accounting-driven turnaround. The caution is what can repeat. Initial BARDA deliveries and severe-burn cases boosted the quarter but are not smooth subscription revenue. Knee procedures remain seasonal and schedulable, while interest income also supports profits. Equity compensation is already deducted in GAAP earnings but added back in operating cash flow, so cash generation and shareholder gains are not interchangeable.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 276.3M | USD 16.5M | USD 24.7M |
| 2024 | USD 237.2M | USD 10.4M | USD -5.8M |
| 2023 | USD 197.5M | USD -3.2M | USD 7.8M |
| 2022 | USD 164.4M | USD -16.7M | USD 10.1M |
| 2021 | USD 156.2M | USD -7.5M | USD 21.1M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | >100x | TTM | Native | USD / USD |
| 2024 | >100x | TTM | Native | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The supplied FY2025 gross margin of 74.4% shows attractive product economics, while the TTM operating margin near 8.3% through Q3 FY2026 shows how much commercial infrastructure and development still absorb. The company's SEC-filed disclosures support a fixed-cost mechanism: rising implant volume spreads manufacturing and selling expenses across more sales, alongside contributions from pricing. That opportunity is structural, but its pace remains disputed. Burlington depreciation continues after construction spending falls, and clinical programs require ongoing funding. Recurring equity awards also explain part of the gap between adjusted presentations and GAAP earnings. Strong seasonal quarters should therefore not become the annual template; durable improvement requires expense growth below sales without assuming away compensation, competition or patient-access costs.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 11M | 4.0% | 6.0% |
| 2024 | USD 4.5M | 1.9% | 4.4% |
| 2023 | USD -6.5M | -3.3% | -1.6% |
| 2022 | USD -17.1M | -10.4% | -10.2% |
| 2021 | USD -7.9M | -5.0% | -4.8% |
Balance sheet and leverage
Vericel's September 2026 10-Q and earnings release report $235.6 million of cash and investments without funded bank debt. The filing-based interpretation identifies roughly $91 million of total operating lease liabilities; lower figures elsewhere refer to long-term portions or remain unreconciled. Leases are fixed operating commitments, not conventional bank borrowings, but they reduce flexibility when production volumes weaken. Liquidity supports development and selective repurchases without dependence on new equity or expensive borrowing. It does not make all cash surplus: clinical commitments, working capital, and NexoBrid royalties or milestones still compete for funding. Repurchase authorizations are optional, and offsetting employee awards may prevent them from shrinking the diluted share count.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 98.3M | USD 137.5M | USD 1.8M net cash | USD -39.2M | 5.03x |
| 2024 | USD 98.9M | USD 116.2M | USD 24.3M net debt | USD -17.4M | 4.23x |
| 2023 | USD 88M | USD 109.6M | USD 19M net debt | USD -21.5M | 4.49x |
| 2022 | USD 47.6M | USD 119.5M | USD 3.5M net cash | USD -72M | 4.99x |
| 2021 | USD 50.2M | USD 103.4M | USD 18.1M net cash | USD -53.2M | 6.08x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company's FY2025 disclosures and Q3 FY2026 filing show a shift from building capacity to using it. Capital spending fell from 27% of revenue during the FY2024 Burlington buildout to below 10% in FY2025, with further restraint subsequently. FDA manufacturing approval makes utilization, rather than another construction cycle, the central investment test. Lower spending releases cash, but does not make cell production asset-light. Facility upkeep, validation, clinical development and depreciation remain relevant; ankle research and overseas access still require investment before revenue. Supplied trailing free-cash-flow estimates are unreconciled, although both interpretations support improvement. Attractive returns on the new plant remain conditional on demand filling it.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 27.2M | USD 27.6M |
| 2024 | USD 64M | USD 24.8M |
| 2023 | USD 27.5M | USD 21M |
| 2022 | USD 7.6M | USD 19.9M |
| 2021 | USD 7.9M | USD 16.3M |
Behind the synthesisVericel: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 11 advisor opinions. The weights and rationales below are retained from that synthesis.
The best-supported common pattern is genuine commercial expansion meeting a demanding valuation: arthroscopic access broadens adoption, completed capacity permits expense absorption, and recurring equity awards reduce shareholder capture. Company filings and FDA records substantiate these mechanisms, but repeated references to the same disclosures are not independent confirmation. Greater weight goes to analyses that distinguish funded debt from leases, adjusted profitability from economic earnings, and existing knee growth from speculative approvals. The strongest bearish case is that ordinary growth normalization can compress the multiple despite successful operations; its severity depends on unproven terminal valuation assumptions. The strongest offset is sustained utilization by established surgeons without needing ankle revenue. Claims of automatic competitive displacement, guaranteed share shrinkage and pricing immunity receive less weight. Unreconciled cash-flow estimates, differing lease definitions and uncertain reimbursement timing prevent a sharper valuation conclusion.
Individual targets retain their original dates. Returns and ratings use the same latest available market close and dividend assumptions as the Consensus.
All 11 opinions
Consensus weight Allocation: 19.0/100. Weight Allocation Rationale: Specific regulatory and filing receipts support the distinction between surgeon access, repeat utilization and shareholder capture. Excluding transformative approvals from baseline earnings improves causal consistency. Higher weight reflects that discipline, not independent confirmation of shared disclosures; the revenue trajectory and retained terminal valuation premium remain important assumptions.
The 1-year target is $57.9 for , with +0.60% expected return and a PARTIAL SELL rating. The 5-year target is $94.6 for , with +64.47% expected return and a BUY rating.
Consensus weight Allocation: 19.0/100. Weight Allocation Rationale: Detailed filing and regulatory references support measured utilization gains, explicit dilution and a baseline excluding ankle approval. Distinguishing outstanding from diluted shares strengthens valuation discipline. The cash-flow reconciliation remains provisional and the terminal multiple uncertain, but transparent limitations justify substantial weight without treating shared primary sources as independent observations.
The 1-year target is $56.7 for , with -1.38% expected return and a PARTIAL SELL rating. The 5-year target is $82.7 for , with +43.80% expected return and a BUY rating.
Consensus weight Allocation: 12.0/100. Weight Allocation Rationale: The analysis connects adoption, manufacturing utilization, recurring compensation and lease commitments into a coherent shareholder-earnings argument. Its evidence overlaps substantially with other company disclosures rather than independently confirming them. Competition and eventual taxation are credible constraints, although their timing and the assumed terminal multiple remain uncertain.
The 1-year target is $59.1 for , with +2.79% expected return and a NEUTRAL rating. The 5-year target is $78.5 for , with +36.42% expected return and a NEUTRAL rating.
Consensus weight Allocation: 7.5/100. Weight Allocation Rationale: Patient-specific production constraints and the later clinical timetable are useful counterweights to frictionless scaling assumptions. The cash-generation mechanism is plausible, but strong future cash margins and systematic share shrinkage remain unproven. Claims that unrelated cartilage programs could immediately obsolete MACI overstate comparability across indications and evidence.
The 1-year target is $52.8 for , with -8.26% expected return and a SELL ALL rating. The 5-year target is $75.1 for , with +30.49% expected return and a NEUTRAL rating.
Consensus weight Allocation: 7.0/100. Weight Allocation Rationale: The bearish case usefully separates business growth from equity valuation and recognizes manufacturing defenses beyond statutory exclusivity. Its distinctive concern survives scrutiny, but rapid competitive displacement and sustained early multiple contraction are assumptions rather than demonstrated outcomes. Long-term leases also should not be compared directly with total lease liabilities.
The 1-year target is $44.0 for , with -23.54% expected return and a SELL ALL rating. The 5-year target is $52.3 for , with -9.02% expected return and a PARTIAL SELL rating.
Consensus weight Allocation: 7.0/100. Weight Allocation Rationale: Primary earnings references, dated analyst commentary and the trial-registry completion estimate add useful evidence. Distinguishing guided adjusted EBITDA from trailing unadjusted earnings also matters. However, biopsies are not guaranteed revenue, categorical dismissal of near-term competition is unsupported, and the terminal enterprise-to-equity bridge is not fully reconciled.
The 1-year target is $60.2 for , with +4.70% expected return and a NEUTRAL rating. The 5-year target is $85.5 for , with +48.72% expected return and a BUY rating.
Consensus weight Allocation: 6.5/100. Weight Allocation Rationale: Commercial adoption, compensation expense and supply concentration provide useful checks on valuation. However, absent lobbying does not establish pricing immunity, scheduled insider sales are weak valuation evidence, and exclusivity expiration does not establish competitive entry. These limitations constrain weight despite a credible operating-growth mechanism.
The 1-year target is $57.3 for , with -0.44% expected return and a PARTIAL SELL rating. The 5-year target is $70.1 for , with +21.81% expected return and a NEUTRAL rating.
Consensus weight Allocation: 6.5/100. Weight Allocation Rationale: The forecast correctly links capacity utilization and repeat adoption to earnings leverage while recognizing rate sensitivity. Its stronger endpoint depends on substantial share shrinkage and margin expansion not established by current repurchases. Overlapping company sources and aggressive ankle-commercialization timing limit the incremental evidentiary contribution.
The 1-year target is $56.7 for , with -1.38% expected return and a PARTIAL SELL rating. The 5-year target is $85.2 for , with +48.13% expected return and a BUY rating.
Consensus weight Allocation: 6.5/100. Weight Allocation Rationale: The report identifies the relevant transmission from discount rates to valuation while recognizing financing resilience. Its adoption and utilization thesis is consistent with disclosed operations. Weight is limited by repeated macro assumptions, overly broad claims of inelastic demand, and share-reduction estimates that require more than the existing authorization.
The 1-year target is $57.9 for , with +0.70% expected return and a PARTIAL SELL rating. The 5-year target is $74.6 for , with +29.61% expected return and a NEUTRAL rating.
Consensus weight Allocation: 5.5/100. Weight Allocation Rationale: Treating equity awards as an economic cost is well supported and challenges automatic buyback accretion. However, the owner-earnings bridge is insufficiently reconciled, and terminal valuation normalization is asserted more strongly than demonstrated. Shared operating facts add limited source independence, so the negative path receives a restrained weight.
The 1-year target is $44.9 for , with -21.90% expected return and a SELL ALL rating. The 5-year target is $53.5 for , with -7.06% expected return and a PARTIAL SELL rating.
Consensus weight Allocation: 3.5/100. Weight Allocation Rationale: The valuation-versus-growth tension is economically sound, so the path remains eligible. Low weight reflects absent research receipts, ambiguous leverage ratios and an unsupported equation of free cash flow with owner earnings. Its directionally cautious insight survives, but provides little independent support beyond better-documented analyses.
The 1-year target is $48.7 for , with -15.25% expected return and a SELL ALL rating. The 5-year target is $63.4 for , with +10.14% expected return and a PARTIAL SELL rating.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v9 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Vericel forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Sources retained from AI Researcher searches
Asset-specific · Researcher web40 available sources from this batch (93 recorded). The first 15 are shown below; expand to read the rest.
Some model providers retained only the consulted domain, not an exact article URL. Those domains are shown as evidence without inventing a link.
- sec.gov sec.gov
- August 23, 2024 Approval Letter - MACI fda.gov
- MACI (autologous cultured chondrocytes on porcine collagen membrane) | FDA fda.gov
- nih.gov nih.gov
- https://www.sec.gov/Archives/edgar/data/887359/000162828026070622/ex991earningsreleaseq32026.htm?utm_source=openai sec.gov
- vcel-20251231 sec.gov
- Post-Approval Studies (PAS) Database accessdata.fda.gov
- A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle clinicaltrials.gov
- Package Insert - MACI fda.gov
- vcel-20260630 sec.gov
- vcel-20260930 sec.gov
- vcel-20260930 sec.gov
- Vericel Corp - Form 8-K - FY2026 sec.gov
- Vericel Corp - Form 8-K - FY2026 sec.gov
- Vericel Corp - Form 8-K - FY2026 sec.gov
Show 25 more sources
- Vericel Corp - Form 8-K - FY2026 sec.gov
- VERICEL CORPORATION - DEF 14A sec.gov
- wa.gov wa.gov
- vcel.com vcel.com
- stocktitan.net stocktitan.net
- biospace.com biospace.com
- tradingkey.com tradingkey.com
- seekingalpha.com seekingalpha.com
- tradingview.com tradingview.com
- investing.com investing.com
- marketbeat.com marketbeat.com
- globenewswire.com globenewswire.com
- mediwound.com mediwound.com
- mordorintelligence.com mordorintelligence.com
- perplexity.ai perplexity.ai
- tickeron.com tickeron.com
- tipranks.com tipranks.com
- biggo.com biggo.com
- bumankle.com bumankle.com
- medpath.com medpath.com
- otcmarkets.com otcmarkets.com
- reportsanddata.com reportsanddata.com
- theinsightpartners.com theinsightpartners.com
- allclinicaltrials.com allclinicaltrials.com
- businessinsider.com businessinsider.com
53 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2026 Year-to-Date Global Market and World-Events Context Through November 14
Download Archived SnapshotCoverage 2026-01-01 to 2026-11-14 · Knowledge cutoff 2026-11-14
January 1-November 14, 2026: persistent inflation, partial oil supply recovery, US midterms and trade, AI financing, and uneven growth.
Archived context covering 2026-01-01 to 2026-11-14. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 96K bytes
- Words
- 14.2K words
- Characters
- 96K characters
- Est. tokens (characters ÷ 4)
- 24K tokens
Fed held at 3.75%-4.00%; Democrats won the next Congress, Nvidia changed leadership and Anthropic filed preliminary IPO terms. Markets through November 13.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| US tariff reset, trade truce and incoming divided government | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-12-31–2026-09-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.
Vericel: forecast questions
What is Vericel (VCEL)'s 1-year price forecast?
Vericel's 1-year target is $55.3 for Nov 2027. The current AI rating is SELL ALL. The expected return from the recorded close is -3.86%, or -3.86% modeled return including net dividends. Latest available market price: USD 57.5, as of 20 Nov 2026. The target date is fixed at publication.
What is Vericel (VCEL)'s 5-year price forecast?
Vericel's 5-year target is $77.8 for Nov 2031. The current AI rating is NEUTRAL. The expected return from the recorded close is +35.26%, or +35.26% modeled return including net dividends. Latest available market price: USD 57.5, as of 20 Nov 2026. The target date is fixed at publication.
How can I compare the AI opinions and audit past Vericel forecasts?
11 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History lists the available batches with their original publication dates.
How does an AI-generated forecast for Vericel differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Vericel is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
If iPulse AI produces thousands of investment reports - work estimated to require over 100,000 traditional analyst hours - isn't that just "AI slop" at scale?
No. iPulse AI produces AI-generated research at scale, but the purpose is depth of analysis, comparison, and accountability. The number of reports is a consequence of the research process; it is not the goal.
iPulse AI does not produce thin copies of existing websites, articles, or investment reports. We use frontier models as an Analytical Intelligence layer. Our Financial Experts select, validate, curate, and supply the input data, including proprietary inputs, so the models work from a prepared evidence base.
In Researcher mode, models can also search the web to check current information, test assumptions, and investigate evidence that may be missing from the supplied data. This can include lobbying expenditure, management developments, regulatory decisions, or other facts relevant to a particular investment thesis. Thinker mode focuses on deep reasoning over the supplied data and context.
Our process goes much further than asking ChatGPT to evaluate a stock. Our team designs structured investment frameworks inspired by the approaches of influential investors, economists, political thinkers, and technological visionaries. These are AI analytical frameworks, not reports written or endorsed by the people who inspired them.
Each asset is analyzed separately through multiple frameworks and configurations, using specialized inputs and task instructions. Different perspectives examine different questions: valuation, business quality, technological disruption, macroeconomic conditions, political influence, financial risks, and more.
Cloud infrastructure allows these workflows to run at scale. That scale also comes with quality assurance at scale: up to 30% of report-generation attempts fail our QA checks. We rerun failed attempts until a clean report passes those checks. Users are presented only with reports that have passed QA.
This explains the volume. The value comes from what we do with the analysis.
A second layer synthesizes the individual reports into an asset-level consensus. This is where we recommend starting when researching a particular asset: it brings together the central thesis, supporting evidence, risks, and disagreements while preserving access to the underlying opinions.
We then compare assets through our proprietary iPulse AI Consensus Score, whose methodology is publicly explained. This helps users move from understanding one asset to comparing opportunities across the analyzed universe.
A further research and editorial layer examines leading candidates, checks current evidence, and develops focused Editorial Top Picks across broad-market and dedicated asset categories. Human editors review the evidence and approve each published edition. For example, explore our Best Long-Term Investments.
But the process does not end when a report is published. We preserve past forecasts so users with the relevant subscription can inspect what the system actually said and compare it with subsequent market outcomes. As more forecasts reach their target dates, the historical record becomes more useful for evaluating which approaches worked, which failed, and under what conditions.
We publish research on our website, arXiv, and Zenodo, alongside explanatory writing on Medium. We use the evidence to refine our data, frameworks, validation, and workflows, and document important findings in Lessons Learned.
The standard we ask users to judge us by is the reasoning, evidence, and historical record behind the research.
How does the iPulse AI Engine work?
The engine runs AI advisor configurations against a shared set of research inputs. The engine history explains the research workflow and what changed between versions.








